Blood cancer and bone marrow cancer

Reading File
Finding Sources
Finding Sources
Finding Sources
Searching Images

blood cancer leukemia bone marrow smear histology

This histology image depicts a tartrate-resistant acid phosphatase (TRAP) stained smear from a bone marrow aspirate in hairy cell leukemia (HCL). The modality is bright-field microscopy. Hairy cell leukemia is a B-cell neoplasm characterized by bone marrow infiltration with mononuclear cells possessing delicate, cytoplasmic, hair-like projections. In TRAP cytochemistry, neoplastic cells exhibit red granular cytoplasmic staining due to tartrate-resistant acid phosphatase activity, a classic diagnostic feature; modern practice often relies on TRAP immunohistochemistry (IHC), which produces brown cytoplasmic positivity but is less specific than the cytochemical method. The image demonstrates scattered medium-to-large cells with abundant cytoplasm and fine cytoplasmic extensions, interspersed among normal hematopoietic elements and adipocytes; many cells show prominent TRAP positivity. Because TRAP activity is labile, slides must be air-dried and stained promptly after preparation. In this example, TRAP IHC has been applied, highlighting hairy cells with cytoplasmic labeling; however, positivity may be observed in other B-cell neoplasms, so interpretation should be integrated with morphology and immunophenotyping (e.g., CD11c, CD25, CD103). Clinically, HCL presents with cytopenias, splenomegaly, and marrow fibrosis; accurate histopathologic diagnosis informs targeted therapy with purine analogs and informs prognosis. This image is educational for hematopathology, cytochemistry, and diagnostic immunohistochemistry practice.

This histology image depicts a tartrate-resistant acid phosphatase (TRAP) stained smear from a bone marrow aspirate in hairy cell leukemia (HCL). The modality is bright-field microscopy. Hairy cell leukemia is a B-cell neoplasm characterized by bone marrow infiltration with mononuclear cells possessing delicate, cytoplasmic, hair-like projections. In TRAP cytochemistry, neoplastic cells exhibit red granular cytoplasmic staining due to tartrate-resistant acid phosphatase activity, a classic diagnostic feature; modern practice often relies on TRAP immunohistochemistry (IHC), which produces brown cytoplasmic positivity but is less specific than the cytochemical method. The image demonstrates scattered medium-to-large cells with abundant cytoplasm and fine cytoplasmic extensions, interspersed among normal hematopoietic elements and adipocytes; many cells show prominent TRAP positivity. Because TRAP activity is labile, slides must be air-dried and stained promptly after preparation. In this example, TRAP IHC has been applied, highlighting hairy cells with cytoplasmic labeling; however, positivity may be observed in other B-cell neoplasms, so interpretation should be integrated with morphology and immunophenotyping (e.g., CD11c, CD25, CD103). Clinically, HCL presents with cytopenias, splenomegaly, and marrow fibrosis; accurate histopathologic diagnosis informs targeted therapy with purine analogs and informs prognosis. This image is educational for hematopathology, cytochemistry, and diagnostic immunohistochemistry practice.

Bone marrow histology on this hematoxylin and eosin–stained section shows diffuse infiltration by mature B-lymphoid cells with prolymphocytic features, partially replacing normal adipocytic marrow. Infiltrating cells are medium to large with round to irregular nuclei, coarse chromatin, conspicuous nucleoli, and scant to moderate cytoplasm. Scattered prolymphocytes are present and background fat cells persist in residual islands; the overall architecture is variably effaced. This pattern is characteristic of bone marrow involvement by B-cell prolymphocytic leukemia (B-PLL). Although immunophenotype cannot be determined on this slide, typical profiles include bright surface immunoglobulin expression with CD19 and CD20 positivity, coexpression of CD5 and FMC7, and often absence of CD23. Clinically, B-PLL affects the elderly and presents with leukocytosis (often >100,000/μL), anemia, thrombocytopenia, and splenomegaly; B symptoms may be present. Relapsed disease can show central nervous system involvement, refractory hypercalcemia, or extramedullary masses. The histopathologic finding confirms marrow involvement and aids staging and management, while recognizing differential diagnoses such as chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, hairy cell leukemia, and acute lymphoblastic leukemia. Integrate complete blood count, flow cytometry immunophenotyping, cytogenetics, and molecular studies for definitive classification and prognosis. This image depicts a bone marrow biopsy/aspirate specimen illustrating B-PLL–related marrow infiltration.

Bone marrow histology on this hematoxylin and eosin–stained section shows diffuse infiltration by mature B-lymphoid cells with prolymphocytic features, partially replacing normal adipocytic marrow. Infiltrating cells are medium to large with round to irregular nuclei, coarse chromatin, conspicuous nucleoli, and scant to moderate cytoplasm. Scattered prolymphocytes are present and background fat cells persist in residual islands; the overall architecture is variably effaced. This pattern is characteristic of bone marrow involvement by B-cell prolymphocytic leukemia (B-PLL). Although immunophenotype cannot be determined on this slide, typical profiles include bright surface immunoglobulin expression with CD19 and CD20 positivity, coexpression of CD5 and FMC7, and often absence of CD23. Clinically, B-PLL affects the elderly and presents with leukocytosis (often >100,000/μL), anemia, thrombocytopenia, and splenomegaly; B symptoms may be present. Relapsed disease can show central nervous system involvement, refractory hypercalcemia, or extramedullary masses. The histopathologic finding confirms marrow involvement and aids staging and management, while recognizing differential diagnoses such as chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, hairy cell leukemia, and acute lymphoblastic leukemia. Integrate complete blood count, flow cytometry immunophenotyping, cytogenetics, and molecular studies for definitive classification and prognosis. This image depicts a bone marrow biopsy/aspirate specimen illustrating B-PLL–related marrow infiltration.

This brightfield light microscopy image depicts a dense bone marrow aspirate smear stained with hematoxylin and eosin. The cellularity is high with a uniform population of small to medium-sized lymphoid cells (lymphoblast-like cells) occupying much of the field. Nuclei are round to ovoid with finely dispersed, coarse chromatin, and scant basophilic cytoplasm; nucleoli are inconspicuous. The architecture is diffuse rather than follicular, with little evidence of erythroid or myeloid precursors; occasional mitotic figures may be present but are not prominent at this magnification. The histology shows a monotonous lymphoid infiltrate, a pattern that raises concern for a lymphoblastic process. Pathologic interpretation would emphasize lymphoid blasts consistent with acute lymphoblastic leukemia or lymphoblastic lymphoma; however, definitive classification requires ancillary studies such as flow cytometry immunophenotyping, immunohistochemistry, and genetic studies (cytogenetics/molecular). Clinically, such a pattern correlates with acute presentations: cytopenias, signs of marrow failure, fatigue, infections, or organomegaly. Potential uses include medical education for recognizing quantitative lymphoid blasts on bone marrow smears, training in differential diagnoses of monomorphic blue cell infiltrates, and optimizing search queries for pathology image datasets. Keywords include: lymphoblasts, pediatric ALL, bone marrow failure, marrow infiltration, hematopathology, immunophenotype, CD markers, prognosis guidance, diagnostic workflow, and educational value overall.

This brightfield light microscopy image depicts a dense bone marrow aspirate smear stained with hematoxylin and eosin. The cellularity is high with a uniform population of small to medium-sized lymphoid cells (lymphoblast-like cells) occupying much of the field. Nuclei are round to ovoid with finely dispersed, coarse chromatin, and scant basophilic cytoplasm; nucleoli are inconspicuous. The architecture is diffuse rather than follicular, with little evidence of erythroid or myeloid precursors; occasional mitotic figures may be present but are not prominent at this magnification. The histology shows a monotonous lymphoid infiltrate, a pattern that raises concern for a lymphoblastic process. Pathologic interpretation would emphasize lymphoid blasts consistent with acute lymphoblastic leukemia or lymphoblastic lymphoma; however, definitive classification requires ancillary studies such as flow cytometry immunophenotyping, immunohistochemistry, and genetic studies (cytogenetics/molecular). Clinically, such a pattern correlates with acute presentations: cytopenias, signs of marrow failure, fatigue, infections, or organomegaly. Potential uses include medical education for recognizing quantitative lymphoid blasts on bone marrow smears, training in differential diagnoses of monomorphic blue cell infiltrates, and optimizing search queries for pathology image datasets. Keywords include: lymphoblasts, pediatric ALL, bone marrow failure, marrow infiltration, hematopathology, immunophenotype, CD markers, prognosis guidance, diagnostic workflow, and educational value overall.

Light microscopy of a bone marrow biopsy from hairy cell leukemia (HCL) shows diffuse infiltration by small to medium lymphoid cells with abundant clear cytoplasm and oval, occasionally reniform nuclei; the cytoplasm creates a fried egg appearance. Hairy projections may be highlighted by immunostaining and by DBA.44 positivity, along with CD11c, CD25, and CD103 markers. The marrow is commonly hypercellular in established disease, whereas early involvement may be hypocellular and mimic aplastic anemia. Prominent reticulin fibrosis is typical and can hinder aspirate yield, making core biopsy essential for assessing infiltration and baseline disease burden. Normal hematopoietic elements, especially the myeloid lineage, are reduced and may display dysplastic changes resembling myelodysplastic syndrome. Plasma cells and mast cells may be mildly increased. In some cases, hairy cells assume a spindle-shaped morphology. The neoplastic cells are typically monotonous with minimal prominent nucleoli, and cytoplasm may exhibit cytoplasmic processes. Unlike several small B-cell lymphomas, discrete cellular aggregates are uncommon, with diffuse replacement predominating. Immunohistochemistry and flow cytometry confirm the diagnosis via characteristic immunophenotype. Clinically, marrow involvement informs staging, prognosis, and treatment planning, though peripheral blood smear and immunophenotypic profiling often suffice for diagnosis. This image, captured at high magnification on a hematoxylin and eosin stained section, showcases classic hairy cell features.

Light microscopy of a bone marrow biopsy from hairy cell leukemia (HCL) shows diffuse infiltration by small to medium lymphoid cells with abundant clear cytoplasm and oval, occasionally reniform nuclei; the cytoplasm creates a fried egg appearance. Hairy projections may be highlighted by immunostaining and by DBA.44 positivity, along with CD11c, CD25, and CD103 markers. The marrow is commonly hypercellular in established disease, whereas early involvement may be hypocellular and mimic aplastic anemia. Prominent reticulin fibrosis is typical and can hinder aspirate yield, making core biopsy essential for assessing infiltration and baseline disease burden. Normal hematopoietic elements, especially the myeloid lineage, are reduced and may display dysplastic changes resembling myelodysplastic syndrome. Plasma cells and mast cells may be mildly increased. In some cases, hairy cells assume a spindle-shaped morphology. The neoplastic cells are typically monotonous with minimal prominent nucleoli, and cytoplasm may exhibit cytoplasmic processes. Unlike several small B-cell lymphomas, discrete cellular aggregates are uncommon, with diffuse replacement predominating. Immunohistochemistry and flow cytometry confirm the diagnosis via characteristic immunophenotype. Clinically, marrow involvement informs staging, prognosis, and treatment planning, though peripheral blood smear and immunophenotypic profiling often suffice for diagnosis. This image, captured at high magnification on a hematoxylin and eosin stained section, showcases classic hairy cell features.

Bone marrow aspirate smear analyzed by light microscopy with high magnification reveals marrow involvement by chronic lymphocytic leukemia (CLL) cells. The predominant population consists of small, dark lymphocytes with scant cytoplasm and condensed, clumped nuclear chromatin, producing high nuclear-to-cytoplasmic ratios. Occasional larger forms and prolymphocytes may be present but are uncommon. A consistent finding is the relative scarcity of cytoplasm and uniform round to slightly irregular nuclei among the bulk of lymphoid cells. The smear may show scattered megakaryocytes, reflecting concurrent hematopoietic activity within the aspirate. Morphology mirrors circulating leukemic cells, consistent with systemic disease. Clinically, such marrow infiltration is associated with cytopenias and advanced disease stage, especially when diffuse, solid infiltration predominates in core biopsy patterns; these patterns correlate with adverse prognosis and with expression of prognostic markers such as ZAP-70. The image corresponds to a high-magnification field intended to document cellular detail rather than architectural marrow patterns. Diagnostic significance lies in confirming lymphoid marrow involvement by CLL, quantifying blast equivalents is not applicable, and differentiating from other small B-cell neoplasms relies on adjunct flow cytometry, cytogenetics, and immunophenotyping. This representation is typical for educational, diagnostic, and research contexts describing CLL marrow morphology.

Bone marrow aspirate smear analyzed by light microscopy with high magnification reveals marrow involvement by chronic lymphocytic leukemia (CLL) cells. The predominant population consists of small, dark lymphocytes with scant cytoplasm and condensed, clumped nuclear chromatin, producing high nuclear-to-cytoplasmic ratios. Occasional larger forms and prolymphocytes may be present but are uncommon. A consistent finding is the relative scarcity of cytoplasm and uniform round to slightly irregular nuclei among the bulk of lymphoid cells. The smear may show scattered megakaryocytes, reflecting concurrent hematopoietic activity within the aspirate. Morphology mirrors circulating leukemic cells, consistent with systemic disease. Clinically, such marrow infiltration is associated with cytopenias and advanced disease stage, especially when diffuse, solid infiltration predominates in core biopsy patterns; these patterns correlate with adverse prognosis and with expression of prognostic markers such as ZAP-70. The image corresponds to a high-magnification field intended to document cellular detail rather than architectural marrow patterns. Diagnostic significance lies in confirming lymphoid marrow involvement by CLL, quantifying blast equivalents is not applicable, and differentiating from other small B-cell neoplasms relies on adjunct flow cytometry, cytogenetics, and immunophenotyping. This representation is typical for educational, diagnostic, and research contexts describing CLL marrow morphology.

High-magnification bright-field light microscopy of a bone marrow hematopoietic smear stained with hematoxylin and eosin reveals a monotonous population of hairy cells adjacent to blood lakes. The neoplastic cells are uniform in size, with round to oval nuclei and inconspicuous nucleoli, and abundant clear cytoplasm creating the classic fried-egg appearance around the nucleus. Cytoplasmic projections (hair-like processes) may be subtle at this magnification but contribute to the characteristic 'hairy' cytology. The background shows scattered erythroid and myeloid cells with preserved but reduced overall marrow cellularity; focal vascular spaces appear as pink blood lakes infiltrated by neoplastic cells. The cells display minimal nuclear atypia, fine chromatin, and a low mitotic rate, consistent with a mature B-cell neoplasm. Immunophenotypic hallmarks, when tested, typically include CD11c, CD25, and CD103 positivity, with BRAF V600E mutation supporting diagnosis of hairy cell leukemia. Clinically, such marrow infiltration can cause cytopenias and splenomegaly; the morphological pattern is critical for prompt diagnosis and to guide targeted therapy (e.g., purine analogs, BRAF inhibitors). This image exemplifies the classic marrow involvement, providing a valuable reference for hematopathology education, differential diagnosis, and histomorphology training in leukemic lymphoid proliferations. Educationally, it reinforces recognition of distinct cytoplasmic clearing and nuclear features for learners.

High-magnification bright-field light microscopy of a bone marrow hematopoietic smear stained with hematoxylin and eosin reveals a monotonous population of hairy cells adjacent to blood lakes. The neoplastic cells are uniform in size, with round to oval nuclei and inconspicuous nucleoli, and abundant clear cytoplasm creating the classic fried-egg appearance around the nucleus. Cytoplasmic projections (hair-like processes) may be subtle at this magnification but contribute to the characteristic 'hairy' cytology. The background shows scattered erythroid and myeloid cells with preserved but reduced overall marrow cellularity; focal vascular spaces appear as pink blood lakes infiltrated by neoplastic cells. The cells display minimal nuclear atypia, fine chromatin, and a low mitotic rate, consistent with a mature B-cell neoplasm. Immunophenotypic hallmarks, when tested, typically include CD11c, CD25, and CD103 positivity, with BRAF V600E mutation supporting diagnosis of hairy cell leukemia. Clinically, such marrow infiltration can cause cytopenias and splenomegaly; the morphological pattern is critical for prompt diagnosis and to guide targeted therapy (e.g., purine analogs, BRAF inhibitors). This image exemplifies the classic marrow involvement, providing a valuable reference for hematopathology education, differential diagnosis, and histomorphology training in leukemic lymphoid proliferations. Educationally, it reinforces recognition of distinct cytoplasmic clearing and nuclear features for learners.

Finding Sources
Finding Sources
Searching Images

multiple myeloma plasma cells bone marrow

Transmission electron microscopy image of bone marrow plasma cells in multiple myeloma, highlighting ultrastructural features of malignant plasmacytosis. The specimen is a bone marrow biopsy/aspirate subjected to TEM to reveal subcellular architecture at high magnification. The primary subject is a plasma cell characterized by a prominent, eccentrically placed nucleus with chunky, irregular clumped chromatin and abundant cytoplasm. Bi- or multinucleation is frequently observed in myeloma cells. The cytoplasm shows extensive rough endoplasmic reticulum organized in parallel lamellae, reflecting heavy immunoglobulin synthesis. Light gray, round to ovoid cytoplasmic inclusions known as Russell bodies are evident within the cytoplasm, representing condensed immunoglobulin within intact endoplasmic reticulum. The cellular borders are well defined, and there is sometimes distension of the ER cisternae near the perinuclear region. The image underscores hallmark features of malignant plasma cells in multiple myeloma and demonstrates both proliferative activity and high secretory load. Clinically, these ultrastructural findings correlate with a high monoclonal immunoglobulin production and marrow infiltration, informing prognosis and therapeutic decisions when integrated with light-chain studies and routine histology. This EM view complements light microscopy by providing evidence of intracellular organelle expansion and intracellular inclusions that are not discernible with conventional staining. Potential educational use includes teaching plasmacytosis, plasma cell neoplasia morphology, and EM-based diagnostic histopathology.

Transmission electron microscopy image of bone marrow plasma cells in multiple myeloma, highlighting ultrastructural features of malignant plasmacytosis. The specimen is a bone marrow biopsy/aspirate subjected to TEM to reveal subcellular architecture at high magnification. The primary subject is a plasma cell characterized by a prominent, eccentrically placed nucleus with chunky, irregular clumped chromatin and abundant cytoplasm. Bi- or multinucleation is frequently observed in myeloma cells. The cytoplasm shows extensive rough endoplasmic reticulum organized in parallel lamellae, reflecting heavy immunoglobulin synthesis. Light gray, round to ovoid cytoplasmic inclusions known as Russell bodies are evident within the cytoplasm, representing condensed immunoglobulin within intact endoplasmic reticulum. The cellular borders are well defined, and there is sometimes distension of the ER cisternae near the perinuclear region. The image underscores hallmark features of malignant plasma cells in multiple myeloma and demonstrates both proliferative activity and high secretory load. Clinically, these ultrastructural findings correlate with a high monoclonal immunoglobulin production and marrow infiltration, informing prognosis and therapeutic decisions when integrated with light-chain studies and routine histology. This EM view complements light microscopy by providing evidence of intracellular organelle expansion and intracellular inclusions that are not discernible with conventional staining. Potential educational use includes teaching plasmacytosis, plasma cell neoplasia morphology, and EM-based diagnostic histopathology.

Bone marrow trephine biopsy prepared for light microscopy and stained with hematoxylin and eosin. The specimen shows bone trabeculae with islands of immature plasma cells dispersed within a background of normal hematopoiesis. In this case, multiple focal lesions are present, reflecting variable tumor burden and disease stage. The neoplastic plasma cells demonstrate a high nuclear-to-cytoplasmic ratio, round to oval nuclei, finely dispersed chromatin, and conspicuous nucleoli. Cytoplasm is scant, and some cells exhibit a plasmacytoid appearance consistent with early myeloma biology. The tumor islands are irregularly distributed and interposed between erythroid, myeloid, and megakaryocytic cells, indicating patchy infiltration rather than uniform replacement. Some large aggregates create focal crowding but do not completely efface the marrow architecture. Mitoses are infrequent in this field. The surrounding hematopoietic marrow appears variably preserved, with preserved megakaryopoiesis in residual areas. These histologic features are compatible with a plasma cell neoplasm and are typical of multiple myeloma in a relatively early focal stage, where trephine sampling may underrepresent overall tumor burden. Clinically, such findings correlate with laboratory monoclonal protein, skeletal surveys, and marrow plasma cell percentage for staging (ISS/RA). The described morphology supports diagnosis and informs prognosis, risk stratification, and treatment decisions in plasma cell myeloma.

Bone marrow trephine biopsy prepared for light microscopy and stained with hematoxylin and eosin. The specimen shows bone trabeculae with islands of immature plasma cells dispersed within a background of normal hematopoiesis. In this case, multiple focal lesions are present, reflecting variable tumor burden and disease stage. The neoplastic plasma cells demonstrate a high nuclear-to-cytoplasmic ratio, round to oval nuclei, finely dispersed chromatin, and conspicuous nucleoli. Cytoplasm is scant, and some cells exhibit a plasmacytoid appearance consistent with early myeloma biology. The tumor islands are irregularly distributed and interposed between erythroid, myeloid, and megakaryocytic cells, indicating patchy infiltration rather than uniform replacement. Some large aggregates create focal crowding but do not completely efface the marrow architecture. Mitoses are infrequent in this field. The surrounding hematopoietic marrow appears variably preserved, with preserved megakaryopoiesis in residual areas. These histologic features are compatible with a plasma cell neoplasm and are typical of multiple myeloma in a relatively early focal stage, where trephine sampling may underrepresent overall tumor burden. Clinically, such findings correlate with laboratory monoclonal protein, skeletal surveys, and marrow plasma cell percentage for staging (ISS/RA). The described morphology supports diagnosis and informs prognosis, risk stratification, and treatment decisions in plasma cell myeloma.

Bone marrow aspirate smear prepared with Wright-Giemsa stain was examined under light microscopy at 40X magnification. The smear demonstrates plasmacytosis with elevated plasma cells, comprising roughly 20% to 35% of nucleated cells in most cases of myeloma; in some preparations the marrow is nearly devoid of other hematopoietic elements due to extensive plasma cell replacement. Morphology spans the spectrum from mature, normal-appearing plasma cells to highly atypical plasmablasts. Mature cells show round to oval nuclei with clumped coarse chromatin and inconspicuous nucleoli; plasmablasts exhibit dispersed chromatin, prominent single nucleolus, and higher nuclear-to-cytoplasmic ratio. The cellular distribution may be diffuse or vaguely patterned with small clusters. This cytologic profile underpins the classification of myeloma variants into mature, intermediate, immature, and plasmablastic forms. Plasmablastic myelomas tend to be highly aggressive, with a poorer prognosis and median survival often less than one year, underscoring the clinical significance of morphologic assessment for risk stratification and treatment planning. The Wright-Giemsa preparation highlights cytoplasmic basophilia, nuclear pleomorphism, and mitotic activity in aggressive foci. This image provides a classic representation of plasmacytosis within marrow, illustrating the diagnostic importance of cellular morphology in multiple myeloma, plasmacytoma, and related plasma cell dyscrasias.

Bone marrow aspirate smear prepared with Wright-Giemsa stain was examined under light microscopy at 40X magnification. The smear demonstrates plasmacytosis with elevated plasma cells, comprising roughly 20% to 35% of nucleated cells in most cases of myeloma; in some preparations the marrow is nearly devoid of other hematopoietic elements due to extensive plasma cell replacement. Morphology spans the spectrum from mature, normal-appearing plasma cells to highly atypical plasmablasts. Mature cells show round to oval nuclei with clumped coarse chromatin and inconspicuous nucleoli; plasmablasts exhibit dispersed chromatin, prominent single nucleolus, and higher nuclear-to-cytoplasmic ratio. The cellular distribution may be diffuse or vaguely patterned with small clusters. This cytologic profile underpins the classification of myeloma variants into mature, intermediate, immature, and plasmablastic forms. Plasmablastic myelomas tend to be highly aggressive, with a poorer prognosis and median survival often less than one year, underscoring the clinical significance of morphologic assessment for risk stratification and treatment planning. The Wright-Giemsa preparation highlights cytoplasmic basophilia, nuclear pleomorphism, and mitotic activity in aggressive foci. This image provides a classic representation of plasmacytosis within marrow, illustrating the diagnostic importance of cellular morphology in multiple myeloma, plasmacytoma, and related plasma cell dyscrasias.

Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching Images

lymphoma Hodgkin Reed-Sternberg cells histology

Histopathology: Light microscopy of an H&E-stained lymph node biopsy. This image highlights classic Reed-Sternberg (RS) cells within a mixed inflammatory background, a hallmark of classic Hodgkin lymphoma (cHL). The RS cells are large (up to ~100 microns) with abundant pale eosinophilic cytoplasm and prominent, bilobed to multinucleate nuclei. The nuclei show vesicular chromatin and thick nuclear membranes, with large central nucleoli creating an owl-eye appearance when two nuclei are juxtaposed. Variants, including giant RS cells and lacunar RS cells, may be seen in different HL subtypes. The surrounding milieu contains eosinophils, neutrophils, mature lymphocytes, plasma cells, and histiocytes, reflecting a characteristic reactive infiltrate. The nodal architecture is variably effaced, sometimes with formation of a rosette-like collar of T lymphocytes around RS cells. Immunophenotyping in practice typically demonstrates CD30 and CD15 positivity with weak PAX5 expression, supporting the HL diagnosis, and helps distinguish RS cells from RS-like cells in non-Hodgkin lymphomas or mimics such as anaplastic carcinoma. This histology provides essential diagnostic confirmatory evidence in suspected HL and informs prognosis and treatment planning (ABVD regimen, radiotherapy, or combined modality therapy). In some cases, classic RS cells may be absent, requiring ancillary testing and correlation with clinical findings, correlating with patient outcome.

Histopathology: Light microscopy of an H&E-stained lymph node biopsy. This image highlights classic Reed-Sternberg (RS) cells within a mixed inflammatory background, a hallmark of classic Hodgkin lymphoma (cHL). The RS cells are large (up to ~100 microns) with abundant pale eosinophilic cytoplasm and prominent, bilobed to multinucleate nuclei. The nuclei show vesicular chromatin and thick nuclear membranes, with large central nucleoli creating an owl-eye appearance when two nuclei are juxtaposed. Variants, including giant RS cells and lacunar RS cells, may be seen in different HL subtypes. The surrounding milieu contains eosinophils, neutrophils, mature lymphocytes, plasma cells, and histiocytes, reflecting a characteristic reactive infiltrate. The nodal architecture is variably effaced, sometimes with formation of a rosette-like collar of T lymphocytes around RS cells. Immunophenotyping in practice typically demonstrates CD30 and CD15 positivity with weak PAX5 expression, supporting the HL diagnosis, and helps distinguish RS cells from RS-like cells in non-Hodgkin lymphomas or mimics such as anaplastic carcinoma. This histology provides essential diagnostic confirmatory evidence in suspected HL and informs prognosis and treatment planning (ABVD regimen, radiotherapy, or combined modality therapy). In some cases, classic RS cells may be absent, requiring ancillary testing and correlation with clinical findings, correlating with patient outcome.

This histology image depicts lymph node tissue from a classic Hodgkin lymphoma with nodular sclerosis. The predominant cells are lacunar variants of Reed-Sternberg (RS) cells, characterized by multilobulated nuclei with coarse chromatin and small nucleoli, and a distinctive perinuclear cytoplasmic condensation that creates clear lacunar spaces in fixed tissues. The lacunae are artifacts of formalin fixation and are not present in B5-fixed specimens. Background comprises a mixed inflammatory milieu with small lymphocytes and scattered eosinophils embedded in fibrous nodules; the nodular architecture is evident with fibrous bands partitioning the lymph node into nodules, a hallmark of nodular sclerosis. RS cells may be solitary and scattered or form compact clusters and, in higher-grade nodular sclerosis (grade II), diffuse sheets. Clinical significance: The presence of lacunar RS cells in a fibrous nodal milieu supports a diagnosis of nodular sclerosis classic Hodgkin lymphoma. Differential considerations include other lymphadenopathies with RS-like cells (reactive conditions, other HL subtypes, or ALCL), but the combination of lacunar morphology, nodular sclerosis, and immunophenotype (CD30+, CD15+, PAX5 weak) is characteristic. This image is relevant for educational demonstrations of HL subtypes, fixation artifacts, and morphology-guided diagnosis, as well as educational references in pathology training and diagnostic review. Educational reference material.

This histology image depicts lymph node tissue from a classic Hodgkin lymphoma with nodular sclerosis. The predominant cells are lacunar variants of Reed-Sternberg (RS) cells, characterized by multilobulated nuclei with coarse chromatin and small nucleoli, and a distinctive perinuclear cytoplasmic condensation that creates clear lacunar spaces in fixed tissues. The lacunae are artifacts of formalin fixation and are not present in B5-fixed specimens. Background comprises a mixed inflammatory milieu with small lymphocytes and scattered eosinophils embedded in fibrous nodules; the nodular architecture is evident with fibrous bands partitioning the lymph node into nodules, a hallmark of nodular sclerosis. RS cells may be solitary and scattered or form compact clusters and, in higher-grade nodular sclerosis (grade II), diffuse sheets. Clinical significance: The presence of lacunar RS cells in a fibrous nodal milieu supports a diagnosis of nodular sclerosis classic Hodgkin lymphoma. Differential considerations include other lymphadenopathies with RS-like cells (reactive conditions, other HL subtypes, or ALCL), but the combination of lacunar morphology, nodular sclerosis, and immunophenotype (CD30+, CD15+, PAX5 weak) is characteristic. This image is relevant for educational demonstrations of HL subtypes, fixation artifacts, and morphology-guided diagnosis, as well as educational references in pathology training and diagnostic review. Educational reference material.

This histopathology image depicts a lymph node biopsy showing features diagnostic of lymphocyte-depleted classic Hodgkin lymphoma, reticular subtype. Using light microscopy on an H&E-stained paraffin section, the lymphoid architecture is markedly effaced by a cellular sheet of large, atypical mononuclear cells with prominent nucleoli. Occasional Reed-Sternberg cells are visible within the expansive background, including cells with multilobed or bilobed nuclei and prominent eosinophilic nucleoli, characteristic of Hodgkin lymphoma. The RS cells are scattered among numerous atypical mononuclear variants rather than forming a cohesive nodular structure. There is little-to-no fibrosis and only sparse non-neoplastic inflammatory cells, which is typical for the lymphocyte-depleted pattern. The background may show rimming by small lymphocytes and histiocytes in a reticular network, but overall cellularity is high. Immunophenotypic markers are not shown here, but in clinical practice RS cells typically express CD30 and CD15 with weaker PAX5 or B-cell markers. The diagnostic significance lies in recognizing the lymphocyte-depleted cHL morphology, which carries distinct clinical implications, often presenting with advanced stage disease and systemic symptoms. This image is useful for educational purposes, differential diagnosis conversation, and correlating histology with treatment planning (ABVD/BEACOPP regimens). Correlation with immunohistochemistry (CD30, CD15, PAX5) and EBV status further supports diagnosis in practice.

This histopathology image depicts a lymph node biopsy showing features diagnostic of lymphocyte-depleted classic Hodgkin lymphoma, reticular subtype. Using light microscopy on an H&E-stained paraffin section, the lymphoid architecture is markedly effaced by a cellular sheet of large, atypical mononuclear cells with prominent nucleoli. Occasional Reed-Sternberg cells are visible within the expansive background, including cells with multilobed or bilobed nuclei and prominent eosinophilic nucleoli, characteristic of Hodgkin lymphoma. The RS cells are scattered among numerous atypical mononuclear variants rather than forming a cohesive nodular structure. There is little-to-no fibrosis and only sparse non-neoplastic inflammatory cells, which is typical for the lymphocyte-depleted pattern. The background may show rimming by small lymphocytes and histiocytes in a reticular network, but overall cellularity is high. Immunophenotypic markers are not shown here, but in clinical practice RS cells typically express CD30 and CD15 with weaker PAX5 or B-cell markers. The diagnostic significance lies in recognizing the lymphocyte-depleted cHL morphology, which carries distinct clinical implications, often presenting with advanced stage disease and systemic symptoms. This image is useful for educational purposes, differential diagnosis conversation, and correlating histology with treatment planning (ABVD/BEACOPP regimens). Correlation with immunohistochemistry (CD30, CD15, PAX5) and EBV status further supports diagnosis in practice.

Reading File
Reading File
Finding Sources
Finding Sources
Now I have comprehensive information to write a thorough answer. Let me compile it all.

Blood Cancers and Bone Marrow Cancers: A Comprehensive Overview

Blood cancers (hematologic malignancies) arise from uncontrolled proliferation of blood-forming cells in the bone marrow, blood, or lymphatic system. They are broadly divided into leukemias, lymphomas, and plasma cell neoplasms (myeloma). All originate in the bone marrow, where hematopoietic stem cells reside.

1. Classification Overview

CategoryCell of OriginExamples
Acute Myeloid Leukemia (AML)Myeloid progenitorAML-M1 to M7 (FAB), core-binding factor AML
Chronic Myeloid Leukemia (CML)Myeloid stem cellBCR-ABL1+ CML
Myelodysplastic Neoplasms (MDS)Myeloid progenitorMDS with del(5q), MDS-EB
Acute Lymphoblastic Leukemia (ALL)Lymphoid progenitorB-ALL, T-ALL
Chronic Lymphocytic Leukemia (CLL)Mature B-cellCLL/SLL
Hodgkin LymphomaB-cell (Reed-Sternberg)Nodular sclerosis, mixed cellularity
Non-Hodgkin Lymphoma (NHL)B- or T-cellFollicular, DLBCL, Burkitt, Mantle cell
Multiple MyelomaPlasma cellMyeloma, MGUS, Plasmacytoma
Myeloproliferative NeoplasmsStem cellPolycythemia vera, Essential thrombocythemia, Myelofibrosis
  • Robbins, Cotran & Kumar Pathologic Basis of Disease, Chapter 13

2. Leukemias

Leukemias are cancers where abnormal white blood cells proliferate uncontrollably in the bone marrow and spill into the blood. They are categorized as acute (rapid onset, immature blast cells) or chronic (slower onset, mature but dysfunctional cells).

Acute Myeloid Leukemia (AML)

AML arises from myeloid progenitor cells and is the most common acute leukemia in adults. Key points:
  • Pathogenesis: Two "hits" are typically required - a mutation that blocks differentiation (e.g., t(8;21) RUNX1-RUNX1T1; inv(16) CBFB-MYH11; t(15;17) PML-RARA) combined with one that promotes proliferation (e.g., FLT3-ITD, KIT mutations)
  • Diagnosis: >20% blasts in bone marrow aspirate (WHO criterion); some cytogenetic subtypes are diagnostic regardless of blast count
  • Presentation: Fever, pallor, fatigue, bleeding, petechiae
  • CBC: Anemia, thrombocytopenia, leukocytosis or leukopenia
  • Special case - APL (M3): t(15;17) PML-RARA - a hematologic emergency due to DIC risk; uniquely responsive to ATRA (all-trans retinoic acid) and arsenic trioxide
  • Treatment: Intensive induction chemotherapy (cytarabine + anthracycline "7+3"); targeted therapy for specific mutations (e.g., FLT3 inhibitors - midostaurin, gilteritinib; IDH inhibitors - enasidenib, ivosidenib); allogeneic stem cell transplant for high-risk disease
  • Prognosis: Overall cure rate ~70% in children; worse in older adults and high-risk cytogenetics
  • Tietz Textbook of Laboratory Medicine, 7th Ed; Swanson's Family Medicine Review

Acute Lymphoblastic Leukemia (ALL)

ALL is the most common pediatric malignancy (peak age 2-5 years). B-cell ALL is far more common than T-cell ALL.
  • Diagnosis: Dense infiltration of bone marrow by lymphoblasts (small cells with scant cytoplasm, fine chromatin, indistinct nucleoli)
  • Genetics: Philadelphia chromosome (BCR-ABL1) occurs in ~20% of adult ALL - confers poor prognosis without TKI therapy; t(12;21) ETV6-RUNX1 is common in children and carries a favorable prognosis
  • Treatment: Multi-agent chemotherapy (induction, consolidation, maintenance); CNS prophylaxis; TKIs (imatinib, dasatinib) for Ph+ ALL; CAR-T cell therapy (tisagenlecleucel) for relapsed/refractory B-ALL
  • Prognosis: ~90% cure rate in children; ~40-50% in adults
Here is a bone marrow aspirate showing lymphoblast infiltration consistent with ALL:
Acute Lymphoblastic Leukemia - bone marrow lymphoblasts

Chronic Myeloid Leukemia (CML)

CML is a myeloproliferative neoplasm defined by the Philadelphia chromosome - a translocation t(9;22) that creates the BCR-ABL1 fusion gene, encoding a constitutively active tyrosine kinase.
  • Epidemiology: Median age ~60 years; ~15% of adult leukemias
  • Phases: Chronic phase → Accelerated phase → Blast crisis (AML-like or ALL-like)
  • Presentation: Splenomegaly, fatigue, night sweats; often asymptomatic (found on routine CBC)
  • CBC: Markedly elevated WBC with all stages of granulocytes (left shift); basophilia is characteristic
  • Treatment (revolution): Imatinib (Gleevec), the first BCR-ABL tyrosine kinase inhibitor (TKI), transformed CML from a fatal disease to one with near-normal life expectancy. Second-generation TKIs (dasatinib, nilotinib, bosutinib) and third-generation (ponatinib) address resistance
  • Monitoring: Quantitative RT-PCR for BCR-ABL1 transcript levels; aim for deep molecular response (MR4.5)
  • Goldman-Cecil Medicine; Braunwald's Heart Disease

Chronic Lymphocytic Leukemia (CLL)

CLL is the most common leukemia in adults in Western countries. It is a B-cell malignancy characterized by small, mature lymphocytes that accumulate in the blood, bone marrow, and lymph nodes.
Bone marrow infiltration in CLL - small dark lymphocytes with clumped chromatin:
CLL bone marrow aspirate showing small lymphocyte infiltration
  • Immunophenotype: CD5+, CD19+, CD20 (dim), CD23+, surface Ig (dim) - this co-expression of CD5 with B-cell markers is pathognomonic
  • Complications: Autoimmune hemolytic anemia, Richter transformation (to DLBCL), hypogammaglobulinemia, infections
  • Staging: Rai (0-IV) or Binet (A-C) staging systems
  • Treatment: Watch-and-wait for asymptomatic early disease; BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) + BCL-2 inhibitor venetoclax are now standard of care for most patients

3. Bone Marrow-Primary Cancers: Myeloma and Related Disorders

Multiple Myeloma

Multiple myeloma is a malignancy of terminally differentiated plasma cells (antibody-secreting B cells) that proliferate in the bone marrow and produce a monoclonal protein (M-protein). It is the second most common blood cancer after NHL.
Multiple myeloma - bone marrow trephine biopsy showing plasma cell infiltration
Multiple myeloma - bone marrow aspirate Wright-Giemsa stain showing plasmacytosis

Diagnostic Criteria - CRAB Features:

FeatureDetail
C - hyperCalcemia>1 mg/dL above normal or >11 mg/dL
R - Renal failureCreatinine >2 mg/dL; light chain nephropathy (cast nephropathy)
A - AnemiaHgb <10 g/dL or >2 g/dL below normal
B - Bone lesionsOsteolytic lesions on X-ray/CT/PET; punched-out skull lesions
Additional "SLiM" criteria (newer): S - >60% plasma cells; Li - serum free light chain ratio ≥100; M - >1 focal MRI lesion
  • Symptom to Diagnosis: An Evidence-Based Guide, 4th ed.; Robbins, Cotran & Kumar

Pathogenesis:

  • Plasma cells home to bone marrow, produce osteoclast-activating factors (IL-1, RANKL), causing bone destruction
  • Monoclonal immunoglobulin (usually IgG or IgA) or free light chains (Bence-Jones proteins) cause kidney injury, amyloidosis, and hyperviscosity
  • Common genetic abnormalities: t(4;14), t(14;16) (poor prognosis); del(17p) TP53 (worst prognosis); t(11;14) (better prognosis)

Treatment:

  • Transplant-eligible: VRd (bortezomib + lenalidomide + dexamethasone) induction → autologous stem cell transplant → lenalidomide maintenance
  • Transplant-ineligible: VRd or DRd (daratumumab + lenalidomide + dexamethasone)
  • Relapsed/refractory: Daratumumab (anti-CD38 monoclonal antibody), pomalidomide, carfilzomib, selinexor, belantamab mafodotin, CAR-T therapy (idecabtagene vicleucel, ciltacabtagene autoleucel)
  • Bisphosphonates (zoledronic acid) or denosumab for bone disease

Spectrum of Plasma Cell Disorders:

  • MGUS (Monoclonal Gammopathy of Undetermined Significance): Premalignant; ~1% per year risk of progression to myeloma
  • Smoldering Multiple Myeloma: Intermediate; higher progression risk; no end-organ damage
  • Plasma Cell Leukemia: >5% plasma cells in peripheral blood or >500/μL - aggressive variant
  • Solitary Plasmacytoma: Single lesion; treated with radiotherapy; ~50% progress to myeloma
  • Goldman-Cecil Medicine; Quick Compendium of Clinical Pathology, 5th ed.

4. Lymphomas

Lymphomas are cancers of lymphocytes that primarily form solid tumor masses in lymph nodes or extranodal tissues, though they frequently involve the bone marrow.

Hodgkin Lymphoma (HL)

Defined by the presence of Reed-Sternberg (RS) cells - large binucleate cells with prominent "owl-eye" nucleoli - embedded in a reactive inflammatory background.
Hodgkin lymphoma - classic Reed-Sternberg cells with owl-eye nucleoli in mixed inflammatory background
  • Immunophenotype: CD30+, CD15+, PAX5 (weak positive), CD45-
  • Subtypes: Nodular Sclerosis (most common, ~70%); Mixed Cellularity; Lymphocyte-rich; Lymphocyte-depleted; Nodular Lymphocyte-Predominant HL (different biology)
  • Association: Epstein-Barr virus (EBV) in a subset
  • Bimodal age distribution: Young adults (15-35 yr) and older adults (>55 yr)
  • Treatment: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) ± radiotherapy; brentuximab vedotin (anti-CD30 ADC) for relapsed disease; checkpoint inhibitors (nivolumab, pembrolizumab) for relapsed/refractory HL
  • Prognosis: >85% cure rate in early stage; ~65-70% in advanced stage

Non-Hodgkin Lymphomas (NHL)

A diverse group of B- and T-cell malignancies. Key examples:
LymphomaKey FeaturesTreatment
Diffuse Large B-Cell Lymphoma (DLBCL)Most common NHL; aggressive; CD20+R-CHOP (rituximab + chemo); CAR-T for relapse
Follicular LymphomaIndolent; t(14;18) BCL2; CD10+, BCL2+Watch-and-wait; R-CHOP; obinutuzumab; EZH2 inhibitors
Burkitt LymphomaHighly aggressive; c-MYC translocation; "starry sky" pattern; EBV-associatedIntensive short-duration chemo (CODOX-M/IVAC)
Mantle Cell LymphomaCD5+, cyclin D1+; t(11;14)BTK inhibitors (ibrutinib, acalabrutinib); intensive chemo + ASCT
Marginal Zone LymphomaIndolent; associated with H. pylori (MALT), HCV, Sjogren'sEradication therapy for H. pylori in gastric MALT
  • Robbins, Cotran & Kumar Pathologic Basis of Disease, Lymphoid Neoplasms chapter

5. Myeloproliferative Neoplasms (MPNs) and MDS

Myeloproliferative Neoplasms

Clonal stem cell disorders with overproduction of mature blood cells:
  • Polycythemia Vera (PV): JAK2 V617F mutation (>95%); excess red cells; risk of thrombosis and transformation to myelofibrosis/AML
  • Essential Thrombocythemia (ET): JAK2/CALR/MPL mutations; excess platelets; thrombotic and hemorrhagic complications
  • Primary Myelofibrosis (PMF): Marrow fibrosis, extramedullary hematopoiesis, splenomegaly; managed with ruxolitinib (JAK1/2 inhibitor) or stem cell transplant

Myelodysplastic Neoplasms (MDS)

MDS involves cytopenias with dysplastic bone marrow morphology and risk of transformation to AML:
  • Common mutations: SF3B1 (favorable), TP53, ASXL1, EZH2 (adverse)
  • del(5q) responds well to lenalidomide
  • High-risk MDS treated with hypomethylating agents (azacitidine, decitabine) or allogeneic transplant

6. Common Presentations and Symptoms

Most blood/bone marrow cancers share overlapping symptoms due to bone marrow failure:
SymptomMechanism
Fatigue, pallorAnemia (decreased RBCs)
Infections, feverNeutropenia (decreased functional WBCs)
Bleeding, petechiaeThrombocytopenia (decreased platelets)
Bone painOsteolysis (myeloma) or marrow expansion
LymphadenopathyLymph node involvement
Splenomegaly/hepatomegalyExtramedullary hematopoiesis or infiltration
Night sweats, weight loss"B symptoms" - systemic inflammatory response

7. Diagnostic Workup

  1. CBC with differential - first clue (cytopenias, blasts, atypical lymphocytes)
  2. Peripheral blood smear - morphology of abnormal cells
  3. Bone marrow aspirate + biopsy - essential for diagnosis, blast %, architecture
  4. Flow cytometry immunophenotyping - identifies cell lineage and aberrant markers
  5. Cytogenetics (karyotype + FISH) - detects chromosomal translocations
  6. Molecular/NGS panel - identifies actionable mutations (FLT3, IDH1/2, NPM1, TP53, etc.)
  7. Serum protein electrophoresis (SPEP) + immunofixation - detects M-protein in myeloma
  8. Imaging - CT/PET (lymphoma staging), skeletal survey/whole-body MRI (myeloma)
  9. LDH, uric acid, beta-2 microglobulin - markers of tumor burden and prognosis

8. General Treatment Modalities

TreatmentApplications
Cytotoxic chemotherapyALL, AML, aggressive NHL
Targeted therapy (TKIs)CML (imatinib, dasatinib), Ph+ ALL, FLT3-mutant AML
Monoclonal antibodiesRituximab (CD20, NHL/CLL), daratumumab (CD38, myeloma), brentuximab (CD30, HL)
Immunomodulatory drugs (IMiDs)Thalidomide, lenalidomide, pomalidomide (myeloma)
Proteasome inhibitorsBortezomib, carfilzomib, ixazomib (myeloma)
BTK inhibitorsIbrutinib, acalabrutinib, zanubrutinib (CLL, MCL)
BCL-2 inhibitorsVenetoclax (CLL, AML)
CAR-T cell therapyRelapsed/refractory B-ALL, DLBCL, myeloma
Stem cell transplantAutologous (myeloma); Allogeneic (AML, ALL, MDS, CML)
Hypomethylating agentsAzacitidine, decitabine (MDS, AML in elderly)
ATRA + arsenic trioxideAPL (AML-M3)
RadiationLocalized NHL, plasmacytoma, HL (involved field)

Summary

Blood cancers span a wide spectrum from rapidly fatal acute leukemias to slow-growing indolent conditions that may not require immediate treatment. The bone marrow is central to most of these diseases - either as the origin of malignant clones or as a site of infiltration. Modern understanding of genetics and molecular pathways has led to a revolution in targeted therapy, particularly for CML (TKIs), APL (ATRA), myeloma (bortezomib, IMiDs, anti-CD38 antibodies), and CLL (BTK + BCL-2 inhibitors). CAR-T cell therapy represents the newest frontier, offering curative potential in previously treatment-refractory disease.
Sources: Robbins, Cotran & Kumar Pathologic Basis of Disease; Goldman-Cecil Medicine; Tietz Textbook of Laboratory Medicine, 7th Ed.; Henry's Clinical Diagnosis and Management by Laboratory Methods; Symptom to Diagnosis: An Evidence-Based Guide, 4th Ed.
This is a shared conversation. Sign in to Orris to start your own chat.